- Country: USA
- Summary: Notice of Contract Award - Orexo US, Inc.
- UST Ref No: 127176706
- Deadline: 24 Sep 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: BARDA-BAA-OrexoNotice
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
Award Notice for Orexo US, Inc. (Contract 75A50125C00010). Clinical development of OX390 (atipamezole) as an α2 agonist reversal agent for human use to counteract the sedative effects of xylazine, medetomidine, and other α2 agonists that are increasingly found in combination with IMF. - Documents:
SAM-Post-Award-Notification-Orexo.pdf
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINNotice of Contract Award - Orexo US, Inc. - USA Tender
The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE, a Government sector organization in USA, has announced a new tender for Notice of Contract Award - Orexo US, Inc.. This tender is published on USARFP under UST Ref No: 127176706 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-09-27.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
